昊帆生物 (301393)

Suzhou Highfine Biotech Co., Ltd.

ASZ

Tags

Contract Research Organization (CXO)New QFII HoldingsWeight Loss DrugsInnovative DrugsChemical Raw Materials and Products ManufacturingBelow IPO PriceHigh-Performing StocksMargin Trading and Securities LendingChiNext Small CapBonus Share Potential

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 10800.00
  • Circulating A-Shares(W): 4210.48
  • Earnings Per Share(RMB): 0.9300
  • Net Assets Per Share(RMB): 21.7539
  • Operating Revenue(W RMB): 43469.82
  • Total Profit(W RMB): 11382.68
  • Net Profit Attributable to Parent(W RMB): 9923.83
  • Net Profit Growth Rate(%): 3.01
  • Weighted Return on Equity(%): 4.3000
  • Operating Cash Flow Per Share(RMB): 0.4420
  • Undistributed Profit Per Share(RMB): 4.8850
  • Capital Reserve Per Share(RMB): 15.6297

2. Main Business

The main business covers:

  • R&D, production, and sales of peptide synthesis reagents

3. Company Basic Information

  • Company Name: Suzhou Highfine Biotech Co., Ltd.
  • Listing Date: 2023-07-12
  • Industry: Manufacturing of Chemical Raw Materials and Chemical Products
  • Address: No. 1 Changting Road, Suzhou High-tech Zone, Jiangsu Province
  • Website: www.highfine.com
  • Company Profile: The company, formerly known as Suzhou Highfine Biotech Co., Ltd., was restructured into a joint-stock company in January 2016. It is primarily engaged in the R&D, production, and sales of peptide synthesis reagents.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Ningbo Haoxin Enterprise Management Consulting Partnership (Limited Partnership) General Legal Person 270.87 6.43
2 China Universal Healthcare Mixed Securities Investment Fund Fund 86.68 2.06
3 Suzhou Highfine Biotech Co., Ltd. Repurchase Special Securities Account General Legal Person 81.81 1.94
4 Abu Dhabi Investment Authority - Proprietary Funds QFII 70.30 1.67
5 Minsheng Securities - CITIC Bank - Minsheng Securities Highfine Biotech Strategic Placement No.1 Collective Asset Management Plan Asset Management Plan 56.81 1.35

5. Concept Sectors

  • CXO Concept
  • Innovative Drugs
  • Weight Loss Drugs
  • Margin Trading & Securities Lending
  • High-Performance Stocks
  • Potential for Bonus Issues
  • Below IPO Price
  • New QFII Holdings
  • SME ChiNext

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information